Info
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
8 anni fa
#advanced, #alk, #cancer, #cancergrace, #center, #egfr, #erlotinib, #grace, #gracecast, #greg, #gregory, #memorial, #molecular, #mutation, #nsclc, #oncology, #rearrangement, #testing, #transition, #treatment
Scopri di più
Cerca
